Cellply
Summary active Updated May 11, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
Cellply is a Bologna, Italy-based deep tech company founded in 2013 by Massimo Bocchi and Roberto Guerrieri that develops analytical tools for the deep characterization of cancer immunotherapies, cell therapies, and cell-based biotherapeutics 12. The company’s flagship product, VivaCyte, combines microfluidics with AI-supported image analysis to enable fully automated characterization of immune cells at high resolution and scale 12. The €7.15M round announced May 11, 2026 was led by ENEA Tech e Biomedical with participation from CDP Venture Capital (via the Fondo Rilancio fund); the capital will fund international expansion of VivaCyte and development of automated quality control procedures for cell therapies 12. Miro Venturi joined the Board as part of the round 2.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-05-11 | Growth | €7.15M | ENEA Tech e Biomedical | CDP Venture Capital 12 |
| 2023-09 | Growth | €3.6M | — | — 3 |
What Investors Say
No independently sourced investor quotes found at this time.
What Founders Say
No independently sourced founder quotes found at this time.
Sources
-
EU-Startups, “Bologna’s Cellply secures €7.15 million to develop tools for faster immunotherapy and cell therapy development,” May 11, 2026. Accessed May 2026. https://www.eu-startups.com/2026/05/bolognas-cellply-secures-e7-15-million-to-develop-tools-for-faster-immunotherapy-and-cell-therapy-development/↩↩↩↩
-
Startbase, “Cellply sammelt 7,15 Millionen Euro,” May 11, 2026. Accessed May 2026. https://www.startbase.com/news/cellply-sammelt-715-millionen-euro↩↩↩↩↩
-
EU-Startups, “Bologna-based Cellply secures €3.6 million setting sights on future growth,” September 2023. Accessed May 2026. https://www.eu-startups.com/2023/09/bologna-based-cellply-secures-e3-6-million-and-sets-sights-on-future-growth/↩